Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Annovis Bio Inc
(NY:
ANVS
)
7.930
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
7.930
Bid (Size)
7.930 (10)
Ask (Size)
8.250 (4)
Prev. Close
7.930
Today's Range
7.930 - 7.930
52wk Range
4.530 - 22.49
Shares Outstanding
13,054,018
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Performance
YTD
-58.11%
-58.11%
1 Month
-5.26%
-5.26%
3 Month
-14.55%
-14.55%
6 Month
-29.07%
-29.07%
1 Year
-12.86%
-12.86%
More News
Read More
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD
September 30, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Addressing Vision Problems Could Lower Risk of Dementia, Study Finds
September 27, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
September 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
September 20, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness
September 06, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients
August 30, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement
August 26, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
August 20, 2024
Via
Investor Brand Network
ANVS Stock Earnings: Annovis Bio Beats EPS for Q2 2024
August 19, 2024
Via
InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months
August 15, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton
August 14, 2024
Via
Investor Brand Network
Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging
August 14, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement
August 14, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap
August 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition
August 06, 2024
Via
Investor Brand Network
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024
August 05, 2024
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.